首页期刊导航|中华医学杂志(英文版)
期刊信息/Journal information
中华医学杂志(英文版)
中华医学会
中华医学杂志(英文版)

中华医学会

照日格图

半月刊

0366-6999

renlihua@cma.org.cn

010-85158321

100710

北京市东城区东四西大街42号

中华医学杂志(英文版)/Journal Chinese Medical JournalCSCDCSTPCD北大核心SCI
查看更多>>1887年创刊,中华医学会主办。中华医学杂志英文版(Chinese Medical Journal)是中华医学会会刊,是中国惟一被SCI核心版收录、具有百年以上历史的医学期刊。重点报道我国医学各学科最新进展和高水平科研成果,目前已被《科学引文索引(SCI)》、《医学索引(IM)》、Medline等国际著名检索系统收录。2009年SCI影响因子0.952,SCI被引频次3407。2010年被国际医学期刊编辑委员会(ICMJE)吸收为新成员。多次获得国家期刊奖、科协专项基金、自然基金等奖项和资助。实行全文上网 (),网上投稿审稿()。
正式出版
收录年代

    Thromboembolic disease in HIV/AIDS:More attention is needed

    Meng HuangChao ChenBingfang YuChuyu Li...
    2647-2650页

    Clinical challenges and research perspectives in liver transplant oncology

    Shengjun XuWenzhi ShuXinyu HeSunbin Ling...
    2651-2653页

    Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome(2024 edition)

    Acquired Immunodeficiency Syndrome Professional Group,Society of Infectious Diseases,Chinese MedicalChinese Center for Disease Control and PreventionTaisheng Li
    2654-2680页
    查看更多>>摘要:The Acquired Immunodeficiency Syndrome Professional Group of the Society of Infectious Diseases of the Chinese Medical Association formulated the first edition of the Chinese Guidelines for the Diagnosis and Treatment of human immunodeficiency virus(HIV)/acquired immune deficiency syndrome(AIDS)(referred to as the Guidelines)in 2005.The 2024 edition of the Guide-lines has been compiled by updating the 2021 fifth edition,incorporating the latest research advancements in antiviral therapy,comprehensive management,opportunistic infections,concurrent tumors,and the prevention and intervention of HIV infection.The new edition also introduces a new section on"Incomplete immune reconstitution",proposes the concept of"HIV vulnerable populations"for the first time with recommendations for their diagnosis and treatment.This edition of the Guidelines covers 14 sections:epidemiology,pathogenic characteristics,laboratory tests,pathogenesis,clinical presentation and staging,diagnostic criteria,common opportunistic infections,antiretroviral therapy,immune reconstitution inflammatory syndrome,incomplete immune reconstitution,AIDS-related neoplasms,prevention of mother-to-child transmission and conception in serodiscordant couples,pre-and post-exposure prophylaxis,and whole-course management of HIV infection.This edition of the Guidelines aims to assist clinical physicians in making informed decisions in the diagnosis,treatment,and management of HIV/AIDS and will be periodically revised and updated based on domestic and international research progress.

    Recommendations for the timing,dosage,and usage of corticosteroids during cytokine release syndrome(CRS)caused by chimeric antigen receptor(CAR)-T cell therapy for hematologic malignancies

    Sanfang TuXiu LuoHeng MeiYongxian Hu...
    2681-2683页

    Consensus for clinical applications of transcranial magnetic resonance-guided focused ultrasound

    Longsheng PanYongqin XiongYongjie LiBomin Sun...
    2684-2686页

    Drug treatment for metabolic dysfunction-associated steatotic liver disease:Progress and direction

    Da ZhouJiangao Fan
    2687-2696页
    查看更多>>摘要:Metabolic dysfunction-associated steatotic liver disease(MASLD),also called non-alcoholic fatty liver disease,is the most epi-demic chronic liver disease worldwide.Metabolic dysfunction-associated steatohepatitis(MASH)is the critical stage of MASLD,and early diagnosis and treatment of MASH are crucial for reducing the incidence of intrahepatic and extrahepatic complications.So far,pharmacotherapeutics for the treatment of MASH are still a major challenge,because of the complexity of the pathogenesis and heterogeneity of MASH.Many agents under investigation have shown impressive therapeutic effects by targeting different key pathways,including the attenuation of steatohepatitis or fibrosis or both.It is notable that thyroid hormone receptor-β ago-nist,resmetirom has become the first officially approved drug for treating MASH with fibrosis.Other agents such as peroxisome proliferator-activated receptor agonists,glucagon-like peptide-1 analogs,and fibroblast growth factor 21 analogs are awaiting approval.This review focuses on the current status of drug therapy for MASH and summarizes the latest results of new medica-tions that have completed phase 2 or 3 clinical trials,and presents the future directions and difficulties of new drug research for MASH.

    Leukocyte immunoglobulin-like receptor B4(LILRB4)in acute myeloid leukemia:From prognostic biomarker to immunotherapeutic target

    Muzi LiXiangyu Zhao
    2697-2711页
    查看更多>>摘要:Leukocyte immunoglobulin-like receptor(LILR)B4(also known as ILT3/CD85k)is an immune checkpoint protein that is highly expressed in solid tumors and hematological malignancies and plays a significant role in the pathophysiology of cancer.LILRB4 is highly expressed in acute myeloid leukemia(AML),and this phenotype is associated with adverse patient outcomes.Its differen-tial expression in tumors compared to normal tissues,its presence in tumor stem cells,and its multifaceted roles in tumorigenesis position it as a promising therapeutic target in AML.Currently,several immunotherapies targeting LILRB4 are undergoing clinical trials.This review summarizes advancements made in the study of LILRB4 in AML,focusing on its structure,ligands,expression,and significance in normal tissues and AML;its protumorigenic effects and mechanisms in AML;and the application of LILRB4-targeted therapies in AML.These insights highlight the potential advantages of LILRB4 as an immunotherapeutic target in the context of AML.

    Association between the triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular diseases in people living with human immunodeficiency virus:Evidence from a retrospectively cohort study 2005-2022

    Liqin SunYinsong LuoXinyun JiaHui Wang...
    2712-2719页
    查看更多>>摘要:Introduction:The triglyceride to high-density lipoprotein cholesterol(TG/HDL-C)ratio,a novel biomarker for metabolic syn-drome(MetS),has been validated in the general population as being significantly correlated with cardiovascular disease(CVD)risk.However,its capabilities to predict CVD in people living with human immunodeficiency virus(HIV;PLWH)remain underexplored.Methods:We conducted a retrospective cohort study of 16,081 PLWH who initiated antiretroviral therapy(ART)at the Third People's Hospital of Shenzhen(China)from 2005 to 2022.The baseline TG/HDL-C ratio was calculated as TG(mmol/L)divided by HDL-C(mmol/L).We employed a multivariate Cox proportional hazards model to assess the association between the TG/HDL-C ratio and CVD occurrence,using Kaplan-Meier curves and log-rank tests to compare survival distributions.The increase in predic-tion risk upon the addition of the biomarker to the conventional risk model was examined through the assessment of changes in net reclassification improvement(NRI)and integrated discrimination improvement(IDI).Nonlinear relationships were investigated using a restricted cubic spline plot,complemented by a two-piecewise Cox proportional hazards model to analyze threshold effects.Results:At the median follow-up of 70 months,213 PLWH developed CVD.Kaplan-Meier curves demonstrated a significant association between the increased risk of CVD and a higher TG/HDL-C ratio(log-rank P<0.001).The multivariate-adjusted Cox proportional hazards regression model indicated that the CVD hazard ratios(HR)(95%confidence intervals[95%CIs])for Q2,Q3,and Q4 versus Q1 of the TG/HDL-C ratio were 2.07(1.24,3.45),2.17(1.32,3.57),and 2.20(1.35,3.58),respectively(P<0.05).The consideration of the TG/HDL-C ratio in the model,which included all significant factors for CVD incidence,improved the predictive risk,as indicated by the reclassification metrics(NRI 16.43%,95%CI 3.35%-29.52%,P=0.014).The restriction cubic spline plot demonstrated an upward trend between the TG/HDL-C ratio and the CVD occurrence(P for non-linear association=0.027,P for overall significance=0.009),with the threshold at 1.013.Significantly positive correlations between the TG/HDL-C ratio and CVD were observed below the TG/HDL-C ratio threshold with HR 5.88(95%CI 1.58-21.88,P=0.008),but not above the threshold with HR 1.01(95%CI 0.88-1.15,P=0.880).Conclusion:Our study confirms the effectiveness of the TG/HDL-C ratio as a predictor of CVD risk in PLWH,which demonstrates a significant nonlinear association.These findings indicate the potential of the TG/HDL-C ratio in facilitating early prevention and treatment strategies for CVD among PLWH.

    Human immunodeficiency virus/acquired immune deficiency syndrome antiretroviral therapy initiated on the same day in treatment-naive people with human immunodeficiency virus:A comparative study of efficacy and regimen

    Jing YuanChanggang DengQisui LiYanyu Sun...
    2720-2725页
    查看更多>>摘要:Background:Rapid initiation of antiretroviral therapy(ART)is recommended by guidelines,however,real-world studies of same-day initiation of ART in China are limited,and an optimal treatment regimen has yet to be identified.The study aims to provide a realistic reference for rapid initiation of ART.Methods:We retrospectively analyzed the clinical data of treatment-naïve people with human immunodeficiency virus(PWHs)who were diagnosed and prescribed same-day ART initiation from January 1,2021 to December 31,2022 at Chongqing Public Health Medical Center.PWHs voluntarily chose an ART regimen that divided them into two groups:National Free Antiretrovi-ral Treatment Program(NFATP)-recommended regimens group(2 nucleoside reverse transcriptase inhibitors+non-nucleoside reverse transcriptase inhibitors/protease inhibitors)and bictegravir/emtricitabine/tenofovir alafenamide(BIC/FTC/TAF)group.The primary endpoint was the virological outcome of the two groups for same-day ART initiation at 24 weeks and 48 weeks.The secondary endpoints included changes in CD4 counts,maintenance of the original ART regimen at 48 weeks,and lipid levels and renal function at 48 weeks.Results:A total of 255 PWHs were included in the study,including 131(51.4%)in the NFATP group and 124(48.6%)in the BIC/FTC/TAF group.The overall virological suppression rates at 24 weeks and 48 weeks were 78.2%(165/211)and 95.4%(207/217),respectively.At 24 weeks,the virologic suppression rate in the NFATP group was lower than that in the BIC/FTC/TAF group(65.3%[66/101]vs.90.0%[99/110],P<0.001).The median increase in the CD4 count was 198.0(126.0-300.0)cells/μL at 24 weeks,with 182.0(108.0-245.0)cells/μL in the NFATP group and 219(132.0-316.0)cells/μL in the BIC/FTC/TAF group(P=0.035).At 48 weeks,there was no significant difference in the virological suppression rate or CD4 count between the groups.The 48-week initial ART regimen retention rates and treatment retention rates were significantly higher in the BIC/FTC/TAF group than in the NFATP group(91.1%(113/124)vs.71.8%(94/131),99.2%(118/119)vs.93.0%(120/129),respectively).In terms of safety,there were no significant changes from baseline in levels of creatinine,estimated glomerular filtration rate(eGFR),or lipids in either group at 48 weeks.Conclusions:ART initiation on the day of diagnosis is effective,safe,and feasible,with satisfactory rates of virologic suppression,48-week initial ART regimen retention rates,and treatment retention rates in treatment-naïve PWHs.In our study,the early virologic suppression rate,CD4 cell counts,and treatment retention of the BIC/FTC/TAF regimens were significantly better than those of the NFATP regimens.

    Corrigendum:Burden of female breast and five gynecological cancers in China and worldwide

    2725页